



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,

12-02-2024

Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

Dear Sir,

Sub: Outcome Of Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Monday, 12th February, 2024**, at the office of company, have inter-alia-

1. Approved the Standalone and Consolidated Unaudited Financial Results and Limited Review Report for the quarter and 9 (Nine) months ended on 31st December, 2023.
2. Acquisition of shares and voting right in Inter Corporate as per Annexure A.

In terms of the Provisions of Regulation 33 and of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Unaudited Financial Results for the quarter and and 9 (Nine) months ended on 31st December, 2023.
2. Limited Review Report for the quarter and and 9 (Nine) months ended on 31st December, 2023.

The meeting of Board of Directors commenced at 03:00 P.M. and concluded at 03:30 P.M.

The above information will be available on the website of the Company i.e <https://titanbiotechltd.com>

This is for your kind information and record please.

Thanking You,

For Titan Biotech Limited



Charanjit Singh
Company Secretary & Compliance Officer
M. No A12726

R.O. & Works: Unit I: A-902A, RIICO Industrial Aea, Phase III, Bhiwadi-301019, Rajasthan
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan
E-mail: hrd@titanbiotechltd.com,accounts@titanbiotechltd.com,,purchase@titanbiotechltd.com
Website: www.titanbiotechltd.com | www.tmmedia.in



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India

Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,

Date: 12/02/2024

Corporate Services Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai- 400001

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations') – Investment in Company

Script Code: 524717

The Company has agreed to acquire 33,90,510 partly paid up equity shares of Rs 24/- each at par aggregating to Rs. 8,13,72,240 (Eight Crore Thirteen Lacs Seventy-Two Thousand Two Hundred Forty Rupees Only) out of which Rs. 2,03,43,060/- (Two Crore Three Lacs Forty-Three Thousand Sixty Rupees Only) will be paid on application (**only application**) by way of subscribing to the rights issue ("said issue") of Titan Media Limited ("Investee Company").

In this regard, the Company agreed to acquire equity shares equivalent to voting rights of 64.58% of the total issued and paid up share capital of the Investee Company whenever the Investee Company will make a further calls on the said issue.

The Company Stake in Investee Company will increase in proportionally on each call. Currently, the Company will pay the 25% on application ("**Tranches 1**") amount and rest will be paid on further calls of the said issue.

The detailed disclosure with respect to the acquisition as required under Regulation 30(6) read with Para A (1) of Part A of Schedule III of the Listing Regulations and the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 is enclosed herewith as '**Annexure – A**'.

We request you to kindly take this on records, and the same be treated as compliance under Regulation 30 and other applicable regulations of the Listing Regulations.

The aforesaid information is also being placed on the website of the Company at <https://titanbiotechltd.com/investor/>

Thanking You.

For Titan Biotech Ltd



Charanjit Singh
Company Secretary
M. No A12726

R.O. & Works: Unit I: A-902A, RIICO Industrial Aea, Phase III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: hrd@titanbiotechltd.com,accounts@titanbiotechltd.com,,purchase@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.tmmedia.in



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

Annexure – A

Details required under the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023

S.N	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Titan Media Ltd (“TML”) is currently engaged in the business of trading of culture media and other related products. <ul style="list-style-type: none"> • Authorized Share Capital (In Rs.): 6,00,00,000; • Paid-up Share Capital (In Rs.): 1,74,99,700 as on date before the said issue; • The turnover of TML for the financial year ended March 31, 2023 was Rs 494.04 lakhs.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Titan Media Ltd (TML) have following common directors i.e Mr. Naresh Kumar Singla and Mr. Suresh Chand Singla, and both are related parties. The transaction falls within the ambit of related party transactions and is at arms’ length. Except to the extent of shares held by the Company in TML, the promoter/promoter group of the Company have no other interest in TML.
3.	Industry to which the entity being acquired belongs	Biological goods Industry (Within the same industry)
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Titan media Ltd. is also in same line of business of trading in Biological goods.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6.	Indicative time period for completion of the acquisition	Maximum 3 (Three) years

R.O. & Works: Unit I: A-902A, RIICO Industrial Aea, Phase III, Bhiwadi-301019, Rajasthan
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: hrd@titanbiotechltd.com,accounts@titanbiotechltd.com,,purchase@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.tmmedia.in



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India

Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration								
8.	Cost of acquisition or the price at which the shares are acquired	<p>The total cost of acquisition for subscribing in the share capital of the TML (Investee Company) will be Rs. 8,13,72,240/- in the said issue.</p> <p>Currently, the company will pay Rs. 2,03,43,060/- on application (“Tranches 1”). The remaining payment will be payable in tranches whenever the Investee Company made the calls for uncalled paid-up share capital (Partly paid up shares) until they become fully paid-up share capital.</p> <p>Current, Cost of Acquisition: Rs. 2,03,43,060/- (“Tranches 1”)</p>								
9.	Percentage of shareholding/ control acquired and/or number of shares acquired	<p>Percentage of Shareholding: 64.58%</p> <p>After the application money paid by TBL and completion of allotment by TML, the Company (TBL) will have the voting right equivalent to 32.29%. Further, voting rights of TBL will increase in subsequent calls made by TML.</p> <p>Number of proposed shares acquired: 33,90,510</p>								
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years’ turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>TML was incorporated under the Companies Act, 1956 on 08/02/1993.</p> <p>TML is engaged in the business of trading of biological products.</p> <p>The turnover of TML for last 3 years is given below:</p> <table border="1" data-bbox="810 1630 1406 1780"> <thead> <tr> <th>Year</th> <th>Turnover (Rs. In Lacs)</th> </tr> </thead> <tbody> <tr> <td>2022-2023</td> <td>Rs. 494.04</td> </tr> <tr> <td>2021-2022</td> <td>Rs.194.46</td> </tr> <tr> <td>2020-2021</td> <td>Rs. 90.27</td> </tr> </tbody> </table> <p>Country of Presence: India</p>	Year	Turnover (Rs. In Lacs)	2022-2023	Rs. 494.04	2021-2022	Rs.194.46	2020-2021	Rs. 90.27
Year	Turnover (Rs. In Lacs)									
2022-2023	Rs. 494.04									
2021-2022	Rs.194.46									
2020-2021	Rs. 90.27									

R.O. & Works: Unit I: A-902A, RIICO Industrial Aea, Phase III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: hrd@titanbiotechltd.com,accounts@titanbiotechltd.com,,purchase@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.tmmedia.in



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and year to date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Titan Biotech Limited (the "Company"), for the quarter and nine month ended December 31, 2023 and the year to date results for the period 1st April 2023 to 31 December 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Report" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

-
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

Akhil Digitally signed
by Akhil Mittal
Date: 2024.02.12
13:14:31 +05'30'
Mittal

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 12.02.2024

Place: New Delhi

UDIN: **24517856BKHCBW3889**

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2023

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	STANDALONE					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	INCOME						
	Revenue from operations	4,597.89	4,342.71	3,033.30	12,415.34	10,716.30	14,399.93
	Other Income	43.70	55.21	27.85	127.10	145.13	194.33
	Total Income	4,641.59	4,397.92	3,061.15	12,542.44	10,861.43	14,594.26
2	EXPENSES						
	Cost of Materials Consumed	2,028.23	2,044.78	1,389.55	5,964.57	5,352.53	7,080.54
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	124.98	77.42	3.60	(232.56)	(102.06)	(93.21)
	Employee Benefit Expenses	602.34	546.57	466.66	1,690.68	1,298.82	1,820.90
	Finance Costs	26.37	27.99	14.26	82.92	48.88	74.59
	Depreciation and Amortization Expenses	83.48	85.98	64.74	249.06	188.95	260.03
	Other Expenses	782.14	802.58	759.57	2,272.35	1,898.32	2,639.80
	Total Expenses	3,647.54	3,585.32	2,698.38	10,027.02	8,685.44	11,782.65
3	Profit/(loss) before exceptional items and tax (1-2)	994.05	812.60	362.77	2,515.42	2,175.99	2,811.61
4	Exceptional Items						
5	Profit/ (loss) before tax (3+4)	994.05	812.60	362.77	2,515.42	2,175.99	2,811.61
6	Tax expense:						
	(I) Current Tax	254.23	209.90	93.04	631.53	543.51	721.44
	(II) Deferred Tax	1.47	2.38	(0.46)	4.59	(2.22)	(8.89)
	(III) Earlier year taxes	-	(2.59)	-	(2.90)	(3.43)	(3.43)
	Total Tax (I+II)	255.70	209.69	92.58	633.22	537.86	709.12
7	Profit (Loss) for the period after Tax (5-6)	738.35	602.91	270.19	1,882.20	1,638.13	2,102.49
8	Other comprehensive income (Net of Tax)						
	Items that will not be reclassified to profit or loss						
A	(i) Re-measurement gain on defined benefit plans	2.07	2.08	-	6.23	-	8.31
	(ii) Income tax relating to these items	(0.52)	(0.52)	-	(1.57)	-	(2.09)
B	Items that will be reclassified to profit or loss						
	(i) Income tax relating to these items						
	Total Other Comprehensive Income for the period (A+B) (net of taxes)	1.55	1.56	-	4.66	-	6.22
9	Total Comprehensive Income for the period (7+8)	739.90	604.47	270.19	1,886.86	1,638.13	2,108.71
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37	826.37
11	Other Equity						9,782.79
12	Earnings per equity share (face value of Rs.10/- each) not annualised						
	(1) Basic	8.93	7.30	3.27	22.78	19.82	25.44
	(2) Diluted	8.93	7.30	3.27	22.78	19.82	25.44


Notes:

- The above unaudited standalone financial results for the quarter and nine months ended on 31.12.2023 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on February 12, 2024. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015. The results for the quarter and nine months ended on 31st Dec. 2023, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and nine months ended on 31st Dec. 2023 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

Naresh Kumar Singla

NARESH KUMAR SINGLA
Managing Director
DIN-00027706



Place : Delhi
Dated : 12.02.2024

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2023

(Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED	
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	Total Income from Operations (Net)	4,641.59	4,397.92	3,061.15	12,542.44	10,861.43	14,594.26
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	994.05	812.60	362.77	2,515.42	2,175.99	2,811.61
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	994.05	812.60	362.77	2,515.42	2,175.99	2,811.61
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	738.35	602.91	270.19	1,882.20	1,638.13	2,102.49
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	739.90	604.47	270.19	1,886.86	1,638.13	2,108.71
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	9,782.79
8	Earning Per Share (of INR 10/- each)						
	(a) Basic	8.93	7.30	3.27	22.78	19.82	25.44
	(b) Diluted	8.93	7.30	3.27	22.78	19.82	25.44


NOTES :

- The above is an extract of the detailed format of standalone unaudited Financial Results for the quarter and nine months ended on 31.12.2023 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone unaudited Financial Results for the said quarter and nine months ended on 31.12.2023 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com. The statutory auditors of the company have carried out a limited review of the aforesaid results.
- The above unaudited standalone financial results for the quarter and nine months ended on 31.12.2023 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on February 12, 2024. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015. The results for the quarter and nine months ended on 31st Dec. 2023, are available on the BSE Limited website (www.bseindia.com) and on the company's Website (www.titanbiotechltd.com).
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and nine months ended on 31.12.2023 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

(Signature)

NARESH KUMAR SINGLA
Managing Director
DIN-00027706



Place : Delhi
Dated : 12.02.2024



A N S K & Associates

CHARTERED ACCOUNTANTS

**OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034**

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and Year to date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Titan Biotech Limited (the "Company") and its Associates, for the quarter and nine month ended December 31, 2023 and the consolidated year to date results for the period from 1 April 2023 to 31 December 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Report" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

-
4. The Statement includes results of the Holding Company -Titan Biotech Limited and Associate Company - Peptech Biosciences Limited.
 5. The accompanying unaudited consolidated financial result includes unaudited interim financial results and other unaudited financial information in respect of its associates which have been approved and furnished to us by the management. Our Conclusion on the statement is not modified in respect of the above matter.
 6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
 7. The unaudited consolidated financial results also includes the Group's share of net loss/profit after tax of Rs. (20.86 lacs) and of Rs. 103.47 and total comprehensive income of Rs. (20.86 Lacs) and of Rs. 103.47 for the Quarter ended 31th December 2023 and for the period 1st April 2023 to 31th December 2023, as considered in the consolidated unaudited financial results, in respect of its Associates, based on their interim financial results of M/s Peptech biosciences Limited which have been reviewed by our Audit Firm. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of its associates, are based solely on such unaudited interim financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

 Digitally signed
by Akhil Mittal
Date: 2024.02.12
13:13:19 +05'30'

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 12.02.2024

Place: New Delhi

UDIN: **24517856BKHCBX7196**

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2023

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	INCOME						
	Revenue from operations	4,597.89	4,342.71	3,033.30	12,415.34	10,716.30	14,399.93
	Other Income	43.70	55.21	27.85	127.10	145.13	194.33
	Total Income	4,641.59	4,397.92	3,061.15	12,542.44	10,861.43	14,594.26
2	EXPENSES						
	Cost of Materials Consumed	2,028.23	2,044.78	1,389.55	5,964.57	5,352.53	7,080.54
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	124.98	77.42	3.60	(232.56)	(102.06)	(93.21)
	Employee Benefit Expenses	602.34	546.57	466.66	1,690.68	1,298.82	1,820.90
	Finance Costs	26.37	27.99	14.26	82.92	48.88	74.59
	Depreciation and Amortization Expenses	83.48	85.98	64.74	249.06	188.95	260.03
	Other Expenses	782.14	802.58	759.57	2,272.35	1,898.32	2,639.80
	Total Expenses	3,647.54	3,585.32	2,698.38	10,027.02	8,685.44	11,782.65
3	Profit/(loss) before exceptional items and tax (1-2)	994.05	812.60	362.77	2,515.42	2,175.99	2,811.61
4	Exceptional Items						
5	Profit/ (loss) before tax (3+4)	994.05	812.60	362.77	2,515.42	2,175.99	2,811.61
6	Tax expense						
	(I) Current Tax	254.23	209.90	93.04	631.53	543.51	721.44
	(II) Earlier year taxes	-	(2.59)	-	(2.90)	(3.43)	(3.43)
	(III) Deferred Tax	1.47	2.38	(0.46)	4.59	(2.22)	(8.89)
	Total Tax (I+II)	255.70	209.69	92.58	633.22	537.86	709.12
7	Profit (Loss) for the period after Tax (5-6)	738.35	602.91	270.19	1,882.20	1,638.13	2,102.49
8	Share in Profit of Associate	(20.88)	49.23	55.97	103.47	351.17	381.93
9	Profit (Loss) for the period (7+8)	717.47	652.14	326.16	1,985.67	1,989.30	2,484.42
10	other comprehensive income (Net of Tax)						
	Items that will not be reclassified to profit or loss						
A	(i) Re-measurement gain on defined benefit plans	2.07	2.08	-	6.23	-	8.31
	(ii) Income tax relating to these items	(0.52)	(0.52)	-	(1.57)	-	(2.09)
B	Items that will be reclassified to profit or loss						
	(i) Income tax relating to these items						
	Total Other Comprehensive Income for the period (A+B) (net of taxes)	1.55	1.56	-	4.66	-	6.22
11	Total Comprehensive Income for the period (7+8)	719.02	653.70	326.16	1,990.33	1,989.30	2,490.64
12	Net profit attributable to:						
	Owners of the holding company						
	Non-controlling interest						
13	Other comprehensive income attributable to :						
	Owners of the holding company						
	Non-controlling interest						
14	Total Comprehensive Income attributable to (10+11)						
	Owners of the holding company						
	Non-controlling interest						
15	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37	826.37
16	Other Equity						10,164.72
17	Earnings per equity share (face value of Rs.10/- each) not annualised						
	(1) Basic	8.68	7.89	3.95	24.03	24.07	30.06
	(2) Diluted	8.68	7.89	3.95	24.03	24.07	30.06

Notes:

- The above consolidated unaudited financial results for the quarter and nine months ended on 31.12.2023 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on February 12, 2024. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter and nine months ended Dec. 31, 2023, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- The consolidated unaudited financial results for the quarter and nine months ended on 31.12.2023 include the results of following - Associate Company - Peptech Biosciences Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019 Accordingly, the Company has recognized provision for income tax for the quarter and nine months ended on 31 Dec. 2023 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India")
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

Naresh Kumar Singla
NARESH KUMAR SINGLA
Managing Director
DIN-00027706



Place : Delhi
Dated : 12.02.2024

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011-71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2023

(Rs. IN LAKHS) except for EPS


S.NO.	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	4,641.59	4,397.92	3,061.15	12,542.44	10,861.43	14,594.26
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	994.05	812.60	362.77	2,515.42	2,175.99	2,811.61
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	994.05	812.60	362.77	2,515.42	2,175.99	2,811.61
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	717.47	652.14	326.16	1,985.67	1,989.30	2,484.42
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	719.02	653.70	326.16	1,990.33	1,989.30	2,490.64
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	10,164.72
8	Earning Per Share (of INR 10/- each)						
	(a) Basic	8.68	7.89	3.95	24.03	24.07	30.06
	(b) Diluted	8.68	7.89	3.95	24.03	24.07	30.06

NOTES :

- The above is an extract of the detailed format of consolidated unaudited Financial Results for the quarter and nine months ended on 31.12.2023 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter and nine months ended on 31st Dec. 2023 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated unaudited financial results for the quarter and nine months ended on 31.12.2023 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on February 12, 2024. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and nine months ended on 31.12.2023 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

(Signature)
NARESH KUMAR SINGLA
Managing Director
DIN-00027706



Place : Delhi
Dated : 12.02.2024